• AZD8055: Identity and Evidence Boundaries

  2026-10-13

  AZD8055 is described by APExBIO as a selective ATP-competitive mTOR kinase inhibitor intended for research on mTORC1 and mTORC2 signaling. Because no matched primary paper or independently verifiable reference was provided, potency, selectivity, biological-outcome, and clinical claims remain supplier-reported rather than independently established here.

• AZD1390 and G4 Replication Stress: Evidence Boundaries

  2026-10-13

  The 2026 Nucleic Acids Research study links REV1–DHX36 coordination to G-quadruplex replication, replication-fork tolerance, and ATM/ATR signaling. AZD1390 is described by APExBIO as a selective ATM kinase inhibitor with preclinical radiosensitizing activity, but the supplied evidence does not establish that it was used in the REV1–DHX36 study or that ATM inhibition directly explains its findings.

• ATP Readouts in p21-ELP Glioblastoma Research

  2026-10-12

  A 2026 in vitro study reported that an elastin-like polypeptide carrying a p21-derived inhibitory peptide reduced proliferation across three glioblastoma cell lines, with differences in sensitivity and limited apoptotic responses. ATP-based luminescence can provide a useful metabolic readout, but the supplied evidence does not establish that the study used APExBIO’s kit or that the findings translate to tumors in vivo.

• IDO1 Blockade and Tumor-Intrinsic STAT3

  2026-10-12

  A 2024 Journal of Immunology study examined why pharmacological IDO1 inhibition may produce complex, tumor-protective effects despite activating antitumor immune cells. Its findings implicate an IL-6–JAK2/STAT3 response in tumor cells, but the evidence remains model-specific and does not establish that AZD1480 or another JAK2 inhibitor improves IDO1-directed therapy.

• AZD1390: ATM Kinase Inhibition in Cancer Research

  2026-10-11

  AZD1390 is a selective ATM kinase inhibitor candidate for studying DNA damage response signaling and preclinical radiosensitization. Product-dossier results report cellular ATM inhibition and enhanced radiation responses, while a separate 2026 study connects REV1–DHX36 dysfunction with G-quadruplex replication stress rather than directly testing AZD1390. https://doi.org/10.1093/nar/gkag562

• AL-8810 and the FP Receptor: From Mechanism to Translation

  2026-10-10

  A thought-leadership analysis of AL-8810 as a research tool for dissecting PGF2α/PTGFR signaling, endometrial vascular remodeling, ERK1/2 activity, and MMP-2 secretion, with emphasis on evidence strength, translational boundaries, and future study design.

• HuR and SVA IRES Translation: Study Insights

  2026-10-09

  A 2026 study identifies the RNA-binding regulator HuR as a positive regulator of Senecavirus A (SVA) internal ribosome entry site translation. Its evidence connects HuR relocalization, viral protein activity, and translation-initiation complex formation, while also defining important limits for extrapolation to other viruses or therapeutic settings.

• 2-APB and ER Calcium Signaling in Starvation

  2026-10-09

  A source-grounded overview of 2-APB as a calcium-signaling research probe, centered on a 2026 Bombyx mori study linking starvation, ER calcium release, calpain activity, autophagy, and apoptosis. The discussion compares direct findings with supplier-reported applications, emphasizing pharmacological specificity, model boundaries, and evidence limitations.

• Cinoxacin: What the 1975 In Vitro Study Showed

  2026-10-08

  Lumish and Norden’s 1975 study established a broad in vitro profile for Cinoxacin against aerobic gram-negative bacilli, while also documenting bactericidal activity, disk diffusion concordance, and readily selected resistance. Its value today lies in defining a historical benchmark for urinary tract infection research and antibiotic resistance studies, not in providing a modern clinical or laboratory protocol.

• REV1–DHX36 Coordination in G4 DNA Replication

  2026-10-08

  A 2026 Nucleic Acids Research study identifies a direct interaction between human REV1 and the G-quadruplex helicase DHX36. The findings support a two-tier model in which REV1 coordinates G4 unwinding with suppression of replication-associated single-stranded DNA gaps, while also defining limits for interpreting ATM and ATR signaling as downstream stress markers.

• DPPH Antioxidant Screening: From Signal to Strategy

  2026-10-07

  DPPH is a valuable chemical probe for comparing radical-scavenging capacity, but its greatest translational value emerges when paired with orthogonal antioxidant, enzyme-inhibition, and chemical-profiling evidence. The 2026 Taihangia rupestris study illustrates how DPPH-informed screening can support sustainable natural-product prioritization without being mistaken for proof of clinical efficacy.

• AZD2461: Reading PARP Response Beyond Viability

  2026-10-07

  AZD2461 is a novel PARP inhibitor whose value extends beyond nanomolar target potency. This analysis connects PARP-1 inhibition, cell-cycle phenotypes, pharmacodynamic timing, and resistance biology while showing why viability alone can misrepresent drug response.

• Azathramycin A: Evidence and Research Context

  2026-10-06

  Azathramycin A is presented in supplier information as a macrolide antibiotic and azithromycin-related degradation product with proposed ribosome-directed activity against Mycobacterium tuberculosis. However, the supplied primary study evaluates kitasamycin in Brachyspira hyodysenteriae and swine, not Azathramycin A or tuberculosis. Its findings therefore provide indirect context for macrolide susceptibility, ribosomal resistance, and evidence interpretation rather than proof of Azathramycin A efficacy. This overview separates catalog claims from published results and outlines appropriate conceptual applications and important translational limits.

• ATG4B, DNA Repair, and AML Progression

  2026-10-06

  A 2025 Advanced Science study identifies energy deficiency-induced nuclear translocation of ATG4B as a mechanistic link between metabolic stress, impaired PRMT1–MRE11 DNA repair, and acute myeloid leukemia progression. Evidence from leukemia cells, a MLLT3-KMT2A mouse model, and patient-derived xenografts supports ATG4B as a contributor to genomic instability, while also leaving important questions about clinical translation and pathway specificity.

• O-GlcNAcylation Rewires Glycolysis in Bone Formation

  2026-10-05

  You et al. identify O-GlcNAcylation as a mechanistic link between Wnt signaling, aerobic glycolysis, and osteoblast-driven bone formation. The study places PDK1 Ser174 modification at the center of this pathway while showing that loss of osteoblast-lineage O-GlcNAcylation weakens Wnt-stimulated bone formation and fracture healing.

8138 records 1/543 page Next 12345 下5页 Last page